Clinical trials: Tumor Burden
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden
This phase II trial evaluates whether a multi-antigen vaccine called STEMVAC improves disease-free survival after surgery in patients with triple-negative breast cancer (TNBC) and moderate or extensive residual cancer burden.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
- Trial name
- NCT07721259
- Testing
- CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Recombinant Granulocyte-Macrophage Colony-Stimulating Factor, Biospecimen Collection
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Washington
Pancreatic Adenocarcinoma
MyCap Mobile Application for Tracking Time Burden of Treatment for Patients With Pancreatic Cancer
This clinical trial tests the feasibility of using the MyCap mobile application (app) for tracking time burden from treatment for patients with pancreatic cancer.
- Trial name
- NCT07619391
- Testing
- Electronic Health Record Review, Smartphone Application-based Intervention, Survey Administration
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Epithelial Ovarian Cancer, Primary Peritoneal
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian…
- Conditions
- Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed
- Trial name
- ATHENA (NCT03522246)
- Testing
- Rucaparib, Nivolumab
- Where
- 238 sites in United States, Australia and 22 more
- Volunteers
- 1,097 people
- Sponsor
- pharmaand GmbH
Cancer Disease, Palliative Therapy
Assessment of Disease Burden and Palliative Care Needs of Patients During the Course of Incurable Cancer Disease
The aim of this non-investigational study is to determine the symptoms and disease burden at the time point of diagnosis and in the further course of an incurable cancer disease.
- Trial name
- APM-Project (NCT02751723)
- Testing
- validated questionnaires
- Where
- 21 sites in Germany
- Volunteers
- 500 people
- Sponsor
- Florian Lordick, MD
Lymphoma
Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00075946
- Testing
- rituximab
- Where
- 483 sites in United States
- Volunteers
- 545 people
- Sponsor
- Eastern Cooperative Oncology Group
Non-Small Cell Lung Cancer
Multicenter Observational Study of Advanced Non-small Cell Lung Cancer With Malignant Pleural Effusion
Multicenter observational study for correlation between tumor mutation burden and immunotherapy efficacy of advanced non-small cell lung cancer with malignant pleural effusion
- Trial name
- NCT04263688
- Testing
- Non-Intervention
- Volunteers
- 300 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Cancer-related Problem/Condition, Quality of Life
A Research Study for Latina Women After Breast Cancer Treatment
The purpose of this study is to examine the effects of a developed psychosocial eHealth intervention on the proposed primary outcomes, health-related quality of life and symptom burden, among Hispanic breast cancer survivors.
- Conditions
- Cancer-related Problem/Condition, Quality of Life, Stress, Emotional
- Trial name
- NCT03645005
- Testing
- "My Guide" (psychoeducation & self-management program), "My Health" (health education program)
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Northwestern University
Myeloproliferative Neoplasm, Primary Myelofibrosis
Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation
The aim of this phase II study is to test a novel concept in the treatment of patients with myeloproliferative neoplasms (MPN), a disease of the bone marrow.
- Conditions
- Myeloproliferative Neoplasm, Primary Myelofibrosis, Essential Thrombocythemia, Polycythemia Vera
- Trial name
- NCT02311569
- Testing
- Mirabegron
- Where
- 11 sites in Switzerland
- Volunteers
- 39 people
- Sponsor
- Swiss Cancer Institute